Azurophil Granule

Azurophil Granule designates the primary lysosomal granules of neutrophils and other myeloid cells containing antimicrobial proteins, proteases, and hydrolytic enzymes including elastase, cathepsin G, myeloperoxidase, and defensins, released during inflammatory responses to degrade pathogens and modulate immune signalling.

The biopharmaceutical industry studies azurophil granule contents in inflammatory disease research and antimicrobial drug development. Neutrophil elastase released from azurophil granules contributes to tissue damage in chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome, making it a therapeutic target for protease inhibitors. Myeloperoxidase serves as a biomarker of neutrophil activation in cardiovascular disease and inflammatory conditions. Defensins from azurophil granules have inspired development of antimicrobial peptide therapeutics. Understanding azurophil granule biology and pathological release mechanisms informs design of anti-inflammatory strategies targeting destructive aspects of neutrophil activation without compromising essential host defence functions.